Methoxamine
Not to be confused with methoxetamine.
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous, intramuscular, oral. |
| Pharmacokinetic data | |
| Bioavailability | 21% (oral), 93% (I.M). |
| Biological half-life | 18.6 hours |
| Excretion | renal |
| Identifiers | |
| CAS Number |
390-28-3 |
| ATC code | C01CA10 (WHO) |
| PubChem | CID 6082 |
| IUPHAR/BPS | 483 |
| DrugBank |
DB00723 |
| ChemSpider |
5857 |
| UNII |
HUQ1KC1YLI |
| KEGG |
D08201 |
| ChEMBL |
CHEMBL524 |
| Chemical data | |
| Formula | C11H17NO3 |
| Molar mass | 211.258 |
| |
| |
| | |
Methoxamine is an α1-adrenergic receptor agonist,[1] similar in structure to phenylephrine and 2,5-DMA. It was developed by Burroughs-Wellcome in the 1940s.[2] The drug induces vasoconstriction of skin and splanchnic blood vessels, thereby increasing peripheral vascular resistance and raising mean arterial blood pressure. Because of its hypertensive effects, it may evoke a compensatory reflex bradycardia via the baroreceptors.
See also
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Monday, April 04, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
